ehealth digital library

Digital library of
the Tanzania
health
community

HIV Patients Treated with Low-dose Prednisolone Exhibit Lower Immune Activation than Untreated Patients.

Kasang, C., Ulmer, A., Donhauser, N., Schmidt, B., Stich, A., Klinker, H., Kalluvya, S., Koutsilieri, E., Rethwilm, A. and Scheller, C. (2012) HIV Patients Treated with Low-dose Prednisolone Exhibit Lower Immune Activation than Untreated Patients. BMC infectious diseases, 12. p. 14. ISSN 1471-2334

[img]
Preview
PDF
Christa_Kasang.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (3MB)

Abstract

HIV-associated general immune activation is a strong predictor for HIV disease progression, suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents may decelerate HIV disease progression. In an observational study, we determined immune activation in HIV patients receiving low-dose (5 mg/day) prednisolone with or without highly-active antiretroviral therapy (HAART) compared to patients without prednisolone treatment. Lymphocyte activation was determined by flow cytometry detecting expression of CD38 on CD8(+) T cells. The monocyte activation markers sCD14 and LPS binding protein (LBP) as well as inflammation markers soluble urokinase plasminogen activated receptor (suPAR) and sCD40L were determined from plasma by ELISA. CD38-expression on CD8+ T lymphocytes was significantly lower in prednisolone-treated patients compared to untreated patients (median 55.40% [percentile range 48.76-67.70] versus 73.34% [65.21-78.92], p = 0.0011, Mann-Whitney test). Similarly, we detected lower levels of sCD14 (3.6 μg/ml [2.78-5.12] vs. 6.11 μg/ml [4.58-7.70]; p = 0.0048), LBP (2.18 ng/ml [1.59-2.87] vs. 3.45 ng/ml [1.84-5.03]; p = 0.0386), suPAR antigen (2.17 μg/ml [1.65-2.81] vs. 2.56 μg/ml [2.24-4.26]; p = 0.0351) and a trend towards lower levels of sCD40L (2.70 pg/ml [1.90-4.00] vs. 3.60 pg/ml [2.95-5.30]; p = 0.0782). Viral load in both groups was similar (0.8 × 105 ng/ml [0.2-42.4 × 105] vs. 1.1 × 105 [0.5-12.2 × 105]; p = 0.3806). No effects attributable to prednisolone were observed when patients receiving HAART in combination with prednisolone were compared to patients who received HAART alone.
Patients treated with low-dose prednisolone display significantly lower general immune activation than untreated patients. Further longitudinal studies are required to assess whether treatment with low-dose prednisolone translates into differences in HIV disease progression.

Item Type: Article
Keywords: HIV, Immune activation, Prednisolone treatment, HAART, T Cell, Monocyte, Antiretroviral therapy
Subjects: HIV > Treatment
Divisions: Other
Depositing User: Mr Joseph Madata
Date Deposited: 11 Dec 2013 06:01
Last Modified: 11 Dec 2013 06:01
URI: http://ihi.eprints.org/id/eprint/2328

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics